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Clenbuterol is a beta-agonist that has been abused by fitness-oriented individuals for muscle growth 
and weight loss. We report a case of a 46-year-old man who presented tachycardic, hypokalemic, and 
hyperglycemic after injecting testosterone obtained from Brazil. He developed refractory hypotension 
and was started on an esmolol infusion for suspected beta-agonist toxicity. Laboratory analysis 
showed a detectable clenbuterol serum concentration. Analysis of an unopened ampule contained 
boldenone undecylenate, clenbuterol, and vitamin E. This case illustrates a novel exposure that 
caused beta-agonist toxicity and was treated successfully with rapid-onset beta blocker. [Clin Pract 
Cases Emerg Med. 2017;1(3):197–200.]
University of Massachusetts School of Medicine, Department of Emergency 
Medicine, Division of Toxicology, Worcester, Massachusetts
University of Massachusetts School of Medicine, Department of Emergency 
Medicine, Worcester, Massachusetts
INTRODUCTION
Clenbuterol is a beta-agonist that has been abused by 
bodybuilders and other fitness-oriented individuals to promote 
muscle growth and weight loss by stimulating the β3 receptor. 
Clenbuterol in the past has been used as an adulterant for heroin.1 
Abuse of clenbuterol may produce hemodynamic compromise, 
life-threatening dysrhythmias and electrolyte disturbance.2 
Toxicity is easily confused with septic shock, but treatment 
is diametrically opposed; vasopressor therapy with additional 
β-agonism is detrimental to patients with clenbuterol toxicity as 
it will promote further tachycardia and subsequent hemodynamic 
collapse. Instead, β-antagonists are appropriate therapy for 
clenbuterol-induced hypotension. 
CASE REPORT
A 46-year-old man with a past medical history significant 
only for a traumatic back injury eight years prior, presented to 
the emergency department (ED) with acute onset of dizziness, 
nausea, and palpitations. His chronic back pain was refractory to 
standard anti-inflammatory medications and local corticosteroid 
injections. Six months prior to our encounter with the patient, 
he experienced symptom relief from a 1 mL intramuscular (IM) 
injection of a reported testosterone of unknown concentration, 
Image 1. Ampule of substance injected by patient with suspected 
clenbuterol toxicity.
which he had received from a friend. He had near-complete 
resolution and remained comfortable for a period of several 
months. The patient reported recurrence of his back pain; thus 
he decided to again attempt testosterone for pain relief. He self-
*
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administered a 2 mL injection of Testex Elmu Prolongatum 250 
mg (testosterone cypionate) (Image 1).
The substance was contained in sealed-glass vials that had 
been purchased from Brazil and imported by a family member 
into the United States. Within minutes of the injection, he 
developed symptoms of palpitations, nausea and vomiting. He 
initially presented to a community hospital; however, he left 
prior to being evaluated by a physician. His symptoms persisted 
and the following day he returned to the same ED, where he 
was observed overnight. Serial troponin levels were negative 
and he was discharged the following day upon improvement of 
his symptoms.
Two months following the previous episode, the patient 
again self-injected intramuscular testosterone. Although 
product lot numbers were unavailable, the patient reported the 
vial originated from the same Brazilian shipment. Again, he 
experienced rapid onset of nausea, vomiting and palpitations. 
He initially presented to an affiliate hospital where he was found 
to have a heart rate of 130 beats per minute (bpm) and a blood 
pressure of 129/66 mmHg. An electrocardiogram (ECG) featured 
a junctional rhythm with QRS and QTc intervals of 92, and 608 
msec respectively, and ST depression in the inferolateral leads 
indicative of myocardial strain (Image 2). 
Labs were remarkable for potassium of 2.6 mmol/L 
(normal range: 3.5-5.3 mmol/L) and serum glucose of 261 mg/
dL. His prolonged QTc was likely due to his hypokalemia. The 
patient denied history of diabetes mellitus. Serum troponin 
concentrations were undetectable (<0.02 ng/mL). Out of concern 
for a possible allergic reaction he was treated with one liter of 
intravenous (IV) normal saline, 50 mg IV diphenhydramine 
and 125 mg IV methylprednisolone. He was also administered 
80 mEq oral potassium and 2 mg IV lorazepam. Subsequently, 
the patient developed acute hypotension with blood pressure 
falling to 70/33 mmHg, and he was given an additional 2.5 
liters of normal saline. Fluid resuscitation failed to resolve his 
hypotension, and the patient was transferred to our tertiary care 
center for further evaluation and care. 
Upon arrival to our facility, the patient’s heart rate was 
120 bpm and he remained hypotensive at 105/43 mmHg. We 
suspected the testosterone preparation contained clenbuterol, and 
out of concern for β-agonist toxicity he was started on esmolol 
(0.5 mg/kg bolus followed by a 50 mcg/kg/min infusion). Shortly 
after titration of esmolol, the patient’s hypotension resolved and 
his tachycardia improved. He remained on the esmolol drip for a 
total of 12 hours. At the time of discharge, his heart rate was 98 
bpm with a blood pressure of 120/66 mmHg. We recommended 
that the patient discontinue use of the testosterone product.
Laboratory workup during the patient’s hospitalization 
included serial troponin serum levels, electrolyte monitoring 
and toxicology screens. Serial ECGs were performed, and the 
patient’s rhythm improved to a sinus tachycardia at a rate of 109 
bpm and a PR interval of 164 ms. The ST depression resolved. 
Serial serum troponin concentrations remained normal. A urine 
comprehensive drug screen (performed by gas chromatography 
mass spectroscopy at our institution) was positive for caffeine and 
diphenhydramine. A quantitative caffeine level drawn two hours 
after the comprehensive drug screen was negative (<1 mcg/mL); 
hence methylxanthine toxicity was deemed unlikely. Qualitative 
analysis performed by NMS Laboratories (Willow Grove, PA) 
showed a positive clenbuterol serum concentration (>10 ng/
mL). An unopened glass ampule provided by the patient was sent 
to NMS’s crime laboratory. It was found to contain boldenone 
undecylenate, clenbuterol, and vitamin E.
DISCUSSION
Differential Diagnosis
The patient in this case presented with tachycardia, 
hypotension, hyperglycemia, and hypokalemia. In developing the 
differential diagnosis and treatment plan for this patient, dividing 
the signs and symptoms into hemodynamic and metabolic 
CPC-EM Capsule
What do we already know about this clinical 
entity? 
Beta-agonist toxicity is described in 
toxicology literature, but it is not well known 
to other specialties. It may go unrecognized 
in the ED setting, as it mimics other 
pathologies such as sepsis.
What makes this presentation of disease 
reportable?
There are no published reports of clenbuterol 
adulterated testosterone.  It is an important 
entity to recognize, as clenbuterol 
adulteration may appear elsewhere, such as 
to “cut” heroin.
What is the major learning point? 
Consider beta-agonist toxicity in patients 
with tachycardia, hypokalemia and 
hyperglycemia. Short-acting beta antagonists 
improve hemodynamic output, particularly in 
hypotensive patients.
How might this improve emergency 
medicine practice? 
Recognize beta-agonist toxicity (which 
mimics other common illnesses) and 
correctly treat it, despite therapy being 
diametrically opposed to “typical” therapy 
for tachycardia in a hypotensive patient.
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categories was an effective approach.3 Hemodynamically the 
patient was tachycardic and hypotensive, while metabolically the 
patient exhibited hyperglycemia and hypokalemia. This method 
will lead to distinct differential diagnoses for each category. 
Subsequently, the potential diagnoses can be compared across 
categories for similarities. 
Toxicological etiologies of tachycardia include 
sympathomimetics, anticholinergics, hallucinogenics, 
β-adrenergic agonists, methylxanthines (such as caffeine or 
theophylline), and drug withdrawal.4 Causes of hypotension 
include alpha-1 adrenergic antagonists (including tricyclic 
antidepressants), alpha-2 adrenergic agonists such as clonidine, 
β-adrenergic agonists, nitrates, carbon monoxide, cyanide, 
opiates, sedative hypnotics, and calcium channel blockers.5,6 
Hyperglycemia can be induced by β-adrenergic agonists, 
methylxanthines, and calcium channel blockers.7,8 Moreover, 
adrenergic agonists, methylxanthines, and diuretics will cause 
hypokalemia.9 Regarding the patient in this vignette, β-adrenergic 
agonists or methylxanthines explained the hemodynamic and 
metabolic abnormalities and suggested the likely toxicological 
etiology. In this presentation, methylxanthine toxicity was less 
likely as the patient did not have the other manifestations of 
severe methylxanthine overdose such as protracted emesis, 
seizure, or altered mental status. 
Pathophysiology
Clenbuterol is an agonist at β1, β2, and β3 receptors. It is 
not approved for human use in the U.S., but is available in 
several European countries and Mexico as a bronchodilator (β2 
agonist) for acute asthma exacerbation.10 Daily regimens range 
from 20-200 mcg given 1-3 times daily. The drug is available 
as an IV/IM injection as well as an oral formulation with a 
bioavailability of 70-80%, and an elimination half-life of 25-39 
hours.11 Clenbuterol is abused by bodybuilders for lean muscle 
development and to reduce adipose tissue. Abuse of clenbuterol 
produces rhabdomyolysis, myocardial infarction, as well as 
life-threatening dysrhythmias and electrolyte disturbance.2,12 
High levels of clenbuterol can cause prolonged tachycardia, 
hypokalemia, and hypophosphatemia.2 
The effects desired by bodybuilders are mediated by 
adipocyte β3 receptors, which stimulate lipolysis to reduce 
adipose tissue, as well as striated muscle β2 agonism, which 
increases muscle mass by nutrient partitioning.13 Toxicity from 
clenbuterol is predominately caused by β2 agonism which 
mediates most of the drug’s toxicity, including tachycardia, 
peripheral vasodilation, hypokalemia, and hyperglycemia. 
In addition to the desired actions of clenbuterol, activation 
of the adrenergic system also leads to undesired side effects via a 
β2 adrenergic G-protein linked receptor. This results in increased 
chronotropy, intracellular shift of potassium and subsequently low 
serum potassium concentrations, and hyperglycemia.3,5,10 Patients 
with clenbuterol toxicity present with tremor, palpitations, 
anxiety, shortness of breath, and vomiting.10,14 Expected vital 
signs include tachycardia and hypotension. Laboratory workup 
may show hyperglycemia, hypokalemia, hypophosphatemia, and 
hypomagnesemia.2,10 In addition, patients may have leukocytosis 
and an anion-gap acidosis.15 
Treatment
Clenbuterol toxicity can be easily confused with septic 
shock, but treatment is diametrically opposed. While intravenous 
crystalloid resuscitation is appropriate in both conditions, 
vasopressor therapy with additional β-agonism is detrimental 
to patients with clenbuterol toxicity as it will promote further 
tachycardia and subsequent hemodynamic collapse. Instead, the 
hemodynamic changes in clenbuterol toxicity should be treated 
Image 2. ECG at time of arrival.
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with β-antagonists.10 Short-acting β-antagonists that allow for 
easy titration, such as esmolol, are preferred. Patients may require 
treatment of up to 72 hours.10 Electrolyte abnormalities should be 
corrected early in the course of treatment. 
Patients who progress to cardiac arrest with ventricular 
tachycardia or fibrillation should receive chest compressions and 
defibrillation, but epinephrine boluses should be withheld as they 
can cause further β-agonism and worsen the patient’s condition. 
There are no data to support this recommendation apart from the 
understanding of the pathophysiology in this toxicity. 
CONCLUSION 
β-agonist toxicity is an uncommon but potentially dangerous 
condition that can be associated with the increased use of 
pharmaceuticals or bodybuilding, increasing fitness, and weight 
loss.12 It has a relatively specific toxidrome that can commonly 
be overlooked when treating the undifferentiated hypotensive, 
tachycardic patient. Definitive treatment of β-agonist toxicity 
is with a β-antagonist; however, this can be counter-intuitive in 
the treatment of the hypotensive patient. We illustrate a case of 
a patient presenting with symptoms mimicking other common 
conditions such as sepsis or anaphylaxis. Emergency clinicians 
must be astute and consider a variety of alternative diagnoses, 
which includes β-agonist toxicity, as the treatment for this is 
diametrically opposed to standard treatments. 
